DGAP-News

MOLOGEN AG presents EnanDIM: A new generation of immunomodulators - Seite 2

action should enable the use in various cancer indications either as
monotherapy, in combination with other targeted therapies or immune
modulators, such as so called checkpoint inhibitors or with other
immunotherapeutic approaches. Furthermore, it could potentially be used in
the field of infectious diseases.

Dr. Matthias Schroff, CEO of MOLOGEN AG, commented: "We are very pleased
about the positive feedback at the OTS meeting. EnanDIM is expected to have
a safety and tolerability profile in clinical tests comparable to the
profile of our lead product MGN1703. Based on its broad immune activation
potential EnanDIM may be used in a variety of indications including cancer
immunotherapy. This again shows our innovative capacity and expertise in
the field of immune therapies and in immuno oncology in particular."

Detailed information on EnanDIM, as discussed at the oral presentation, is
summarized in the poster with the title "EnanDIM: A new class of
enantiomeric oligodeoxynucleotides for TLR‐9 activation" (poster no. 056).

For more information please visit the OTS website
www.oligotherapeutics.org.

MOLOGEN's proprietary TLR-9 agonist and cancer immune therapy MGN1703 is
currently being investigated in the phase III clinical trial IMPALA for
first-line maintenance treatment of metastatic colorectal cancer. The trial
is being conducted in eight European countries, including the five major
pharma markets.

Furthermore, MGN1703 is being investigated for first-line maintenance
treatment of extensive-stage small cell lung cancer, a serious cancer
disease with high unmet medical need. IMPULSE, an international randomized
controlled trial, is currently enrolling patients as well.

For more information of the IMPALA and IMPULSE trials, visit
www.clinicaltrials.gov.


About EnanDIM(R)
EnanDIM(R) (Enantiomeric, DNA-based, ImmunoModulator) is an innovative
linear DNA-based TLR-9 agonist in pre-clinical development. It broadly and
strongly activates the immune system. EnanDIM(R) could be used in various
cancer indications either as monotherapy, in combination with other
targeted therapies or immune modulators, such as so called checkpoint
inhibitors, or with other immunotherapeutic approaches. It could also
potentially be used in the field of infectious diseases.

About MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and
clinical development of cancer immune therapies and DNA vaccines against
infectious diseases.

The cancer immune therapy MGN1703 is the company's lead product and
best-in-class TLR-9 agonist. It is currently developed for first-line
maintenance treatment of colorectal cancer (pivotal randomized trial) and